Noom, a digital healthcare company focused on chronic disease prevention and healthy living, has announced a partnership with Gifthealth, the LillyDirect® pharmacy provider of Eli Lilly and Company. This collaboration aims to simplify access to FDA-approved Zepbound® (tirzepatide) single-dose vials for Noom members who have an on-label prescription from their physician.
This integration marks an evolution in Noom’s approach to weight management, enhancing support for members prescribed FDA-approved medications. Since introducing branded medications in 2023, Noom has remained committed to making patient experiences simpler and more accessible.
Through its collaboration with LillyDirect/Gifthealth, Noom will offer members real-time fill-status and shipping updates for their Zepbound® prescriptions directly within the Noom interface, improving transparency and convenience.
Beyond access to medication, Noom provides a comprehensive GLP-1 companion program to help members develop lasting healthy habits. This includes a GLP-1 Med Tracker for reminders, logging, and side-effect support, protein-focused nutrition support with tools like photo meal logging to maintain lean mass, a Muscle Defense™ exercise plan with personalized movement goals and resistance training, and educational resources tailored specifically to Zepbound® and its single-dose vials.
The new integration will begin rolling out to Noom members in mid-April.
“The label on each FDA-approved GLP-1 medication makes clear they are to be used as an adjunct to a reduced-calorie diet and increased physical activity. We built Noom GLP-1 Companion with Muscle Defense™ to be that program,” said Geoff Cook, Chief Executive Officer of Noom. “We applaud Lilly’s decision to offer Zepbound® in a more affordable vial format to cash-pay patients, which aligns with Noom’s mission to empower everyone, everywhere to live better longer.”
Click here to read the original news story.